GeoVax Labs, Inc.
GOVXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the. The $2.5M market capitalization puts GOVX squarely in micro-cap range for its industry. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Market Cap
$2.5M
Beta
3.65
P/E (TTM)
—
P/E (Fwd)
-0.56
EPS (TTM)
$-5.62
EPS (Fwd)
$-0.86
ROE
-891.6%
ROA
-256.8%
Cash
$3.1M
Total Debt
$323,141
Free CF
-$10.8M
52W Change
-97.2%
Annual Financials
Cash vs Debt
Where GOVX stands vs its 150-day and 200-day moving averages
As of the August 11, 2026 close, GOVX finished 56.90% below its 150-day moving average ($1.74) and 80.16% below its 200-day moving average ($3.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GOVX overbought or oversold?
At the August 11, 2026 close, GOVX's RSI(14) was 28.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
GeoVax Labs, Inc. holds $3.1M in cash against $323K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$10.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -891.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $82K to $2.5M.
GeoVax Labs, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing GOVX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.